|
1
|
Zhang S, Cai Z, Li H. AHNAKs roles in physiology and malignant tumors. Front Oncol 2023; 13:1258951. [PMID: 38033502 PMCID: PMC10682155 DOI: 10.3389/fonc.2023.1258951] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2023] [Accepted: 10/30/2023] [Indexed: 12/02/2023] Open
Abstract
The AHNAK family currently consists of two members, namely AHNAK and AHNAK2, both of which have a molecular weight exceeding 600 kDa. Homologous sequences account for approximately 90% of their composition, indicating a certain degree of similarity in terms of molecular structure and biological functions. AHNAK family members are involved in the regulation of various biological functions, such as calcium channel modulation and membrane repair. Furthermore, with advancements in biological and bioinformatics technologies, research on the relationship between the AHNAK family and tumors has rapidly increased in recent years, and its regulatory role in tumor progression has gradually been discovered. This article briefly describes the physiological functions of the AHNAK family, and reviews and analyzes the expression and molecular regulatory mechanisms of the AHNAK family in malignant tumors using Pubmed and TCGA databases. In summary, AHNAK participates in various physiological and pathological processes in the human body. In multiple types of cancers, abnormal expression of AHNAK and AHNAK2 is associated with prognosis, and they play a key regulatory role in tumor progression by activating signaling pathways such as ERK, MAPK, Wnt, and MEK, as well as promoting epithelial-mesenchymal transition.
Collapse
Affiliation(s)
- Shusen Zhang
- Hebei Province Xingtai People’s Hospital Postdoctoral Workstation, Xingtai, China
- Postdoctoral Mobile Station, Hebei Medical University, Shijiazhuang, China
- Department of Pulmonary and Critical Care Medicine, Affiliated Xing Tai People Hospital of Hebei Medical University, Xingtai, China
- The First Department of Pulmonary and Critical Care Medicine, The Second Hospital of Hebei Medical University, Shijiazhuang, China
| | - Zhigang Cai
- Postdoctoral Mobile Station, Hebei Medical University, Shijiazhuang, China
- The First Department of Pulmonary and Critical Care Medicine, The Second Hospital of Hebei Medical University, Shijiazhuang, China
| | - Hui Li
- Department of surgery, Affiliated Xing Tai People Hospital of Hebei Medical University, Xingtai, China
| |
Collapse
|
|
2
|
Katsumata H, Matsumoto K, Yanagita K, Shimizu Y, Hirano S, Kitajima K, Koguchi D, Ikeda M, Sato Y, Iwamura M. Expression of S100A16 Is Associated with Biological Aggressiveness and Poor Prognosis in Patients with Bladder Cancer Who Underwent Radical Cystectomy. Int J Mol Sci 2023; 24:14536. [PMID: 37833982 PMCID: PMC10572706 DOI: 10.3390/ijms241914536] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2023] [Revised: 09/22/2023] [Accepted: 09/24/2023] [Indexed: 10/15/2023] Open
Abstract
S100 calcium binding protein A16 (S100A16) is expressed in various cancers; however, there are few reports on S100A16 in bladder cancer (BC). We retrospectively investigated clinical data including clinicopathological features in 121 patients with BC who underwent radical cystectomy (RC). Immunohistochemical staining was performed to evaluate S100A16 expression in archived specimens. Cases with >5% expression and more than moderate staining intensity on cancer cells were considered positive. S100A16 expression was observed in 54 patients (44.6%). Univariate analysis showed that S100A16 expression was significantly associated with age, pT stage, recurrence, and cancer-specific death. Kaplan-Meier analyses showed that patients with S100A16 expression had shorter overall survival (OS), cancer-specific survival (CSS), and recurrence-free survival (RFS) than those without S100A16 expression. In multivariate analysis, pT stage was an independent prognostic factor for OS and lymph node metastasis for CSS and RFS. S100A16 expression may be a biomarker of a biologically aggressive phenotype and poor prognosis in patients with BC who underwent RC. The PI3k/Akt signaling pathway is probably associated with S100A16 and may be a therapeutic target.
Collapse
Affiliation(s)
- Hiroki Katsumata
- Department of Urology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-ku, Sagamihara 252-0374, Kanagawa, Japan; (H.K.); (Y.S.); (S.H.); (K.K.); (D.K.); (M.I.); (Y.S.); (M.I.)
| | - Kazumasa Matsumoto
- Department of Urology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-ku, Sagamihara 252-0374, Kanagawa, Japan; (H.K.); (Y.S.); (S.H.); (K.K.); (D.K.); (M.I.); (Y.S.); (M.I.)
| | - Kengo Yanagita
- Biofluid Biomarker Center, Niigata University, 8050 ikarashi 2-no-cho, Nishi-ku, Niigata 950-2181, Niigata, Japan;
| | - Yuriko Shimizu
- Department of Urology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-ku, Sagamihara 252-0374, Kanagawa, Japan; (H.K.); (Y.S.); (S.H.); (K.K.); (D.K.); (M.I.); (Y.S.); (M.I.)
| | - Shuhei Hirano
- Department of Urology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-ku, Sagamihara 252-0374, Kanagawa, Japan; (H.K.); (Y.S.); (S.H.); (K.K.); (D.K.); (M.I.); (Y.S.); (M.I.)
| | - Kazuki Kitajima
- Department of Urology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-ku, Sagamihara 252-0374, Kanagawa, Japan; (H.K.); (Y.S.); (S.H.); (K.K.); (D.K.); (M.I.); (Y.S.); (M.I.)
| | - Dai Koguchi
- Department of Urology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-ku, Sagamihara 252-0374, Kanagawa, Japan; (H.K.); (Y.S.); (S.H.); (K.K.); (D.K.); (M.I.); (Y.S.); (M.I.)
| | - Masaomi Ikeda
- Department of Urology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-ku, Sagamihara 252-0374, Kanagawa, Japan; (H.K.); (Y.S.); (S.H.); (K.K.); (D.K.); (M.I.); (Y.S.); (M.I.)
| | - Yuichi Sato
- Department of Urology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-ku, Sagamihara 252-0374, Kanagawa, Japan; (H.K.); (Y.S.); (S.H.); (K.K.); (D.K.); (M.I.); (Y.S.); (M.I.)
- KITASATO-OTSUKA Biomedical Assay Laboratories Co., Ltd., 1-15-1 Kitasato, Minami-ku, Sagamihara 252-0329, Kanagawa, Japan
| | - Masatsugu Iwamura
- Department of Urology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-ku, Sagamihara 252-0374, Kanagawa, Japan; (H.K.); (Y.S.); (S.H.); (K.K.); (D.K.); (M.I.); (Y.S.); (M.I.)
| |
Collapse
|
|
3
|
Hirano S, Matsumoto K, Tanaka K, Amano N, Koguchi D, Ikeda M, Shimizu Y, Tsuchiya B, Nagashio R, Sato Y, Iwamura M. DJ-1 Expression Might Serve as a Biologic Marker in Patients with Bladder Cancer. Cancers (Basel) 2022; 14:2535. [PMID: 35626138 PMCID: PMC9139869 DOI: 10.3390/cancers14102535] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2022] [Revised: 04/29/2022] [Accepted: 05/19/2022] [Indexed: 02/03/2023] Open
Abstract
The overexpression of DJ-1 protein and its secretion into the bloodstream has been reported in various neoplasms. However, serum levels and the subcellular localization of DJ-1 have not been analyzed in detail in bladder cancer (BC). Our comprehensive analysis of these variables started with the measurement of DJ-1 in serum from 172 patients with BC, 20 patients with urolithiasis and 100 healthy participants. Next, an immunohistochemical study of DJ-1 expression and localization was conducted in 92 patients with BC, and associations with clinicopathologic factors and patient outcomes were evaluated. Serum DJ-1 was significantly higher in patients with BC than in those with urolithiasis or in healthy participants. Immunohistochemically, a cytoplasm-positive (Cy+) and nucleus-negative (N-) DJ-1 pattern was associated with age and pathologic stage. Log-rank tests indicated that the Cy+, N- pattern was significantly associated with overall survival (OS), recurrence-free survival (RFS), and cancer specific survival (CSS). In addition, the Cy+, N- pattern was an independent prognostic factor in the multivariate analysis adjusted for the effects of the clinicopathologic outcomes. The investigation of DJ-1 expression might help physicians to make decisions regarding further follow-up and additional treatments.
Collapse
Affiliation(s)
- Shuhei Hirano
- Department of Urology, School of Medicine, Graduate School of Medical Sciences, Kitasato University, Sagamihara 252-0374, Japan; (S.H.); (N.A.); (D.K.); (M.I.); (Y.S.); (Y.S.); (M.I.)
| | - Kazumasa Matsumoto
- Department of Urology, School of Medicine, Graduate School of Medical Sciences, Kitasato University, Sagamihara 252-0374, Japan; (S.H.); (N.A.); (D.K.); (M.I.); (Y.S.); (Y.S.); (M.I.)
| | - Kei Tanaka
- Department of Applied Tumor Pathology, Graduate School of Medical Sciences, Kitasato University, Sagamihara 252-0374, Japan; (K.T.); (B.T.); (R.N.)
- Department of Pathology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8501, Japan
| | - Noriyuki Amano
- Department of Urology, School of Medicine, Graduate School of Medical Sciences, Kitasato University, Sagamihara 252-0374, Japan; (S.H.); (N.A.); (D.K.); (M.I.); (Y.S.); (Y.S.); (M.I.)
| | - Dai Koguchi
- Department of Urology, School of Medicine, Graduate School of Medical Sciences, Kitasato University, Sagamihara 252-0374, Japan; (S.H.); (N.A.); (D.K.); (M.I.); (Y.S.); (Y.S.); (M.I.)
| | - Masaomi Ikeda
- Department of Urology, School of Medicine, Graduate School of Medical Sciences, Kitasato University, Sagamihara 252-0374, Japan; (S.H.); (N.A.); (D.K.); (M.I.); (Y.S.); (Y.S.); (M.I.)
| | - Yuriko Shimizu
- Department of Urology, School of Medicine, Graduate School of Medical Sciences, Kitasato University, Sagamihara 252-0374, Japan; (S.H.); (N.A.); (D.K.); (M.I.); (Y.S.); (Y.S.); (M.I.)
| | - Benio Tsuchiya
- Department of Applied Tumor Pathology, Graduate School of Medical Sciences, Kitasato University, Sagamihara 252-0374, Japan; (K.T.); (B.T.); (R.N.)
| | - Ryo Nagashio
- Department of Applied Tumor Pathology, Graduate School of Medical Sciences, Kitasato University, Sagamihara 252-0374, Japan; (K.T.); (B.T.); (R.N.)
| | - Yuichi Sato
- Department of Urology, School of Medicine, Graduate School of Medical Sciences, Kitasato University, Sagamihara 252-0374, Japan; (S.H.); (N.A.); (D.K.); (M.I.); (Y.S.); (Y.S.); (M.I.)
- Department of Applied Tumor Pathology, Graduate School of Medical Sciences, Kitasato University, Sagamihara 252-0374, Japan; (K.T.); (B.T.); (R.N.)
| | - Masatsugu Iwamura
- Department of Urology, School of Medicine, Graduate School of Medical Sciences, Kitasato University, Sagamihara 252-0374, Japan; (S.H.); (N.A.); (D.K.); (M.I.); (Y.S.); (Y.S.); (M.I.)
| |
Collapse
|
|
4
|
Serum Epiplakin Might Be a Potential Serodiagnostic Biomarker for Bladder Cancer. Cancers (Basel) 2021; 13:cancers13205150. [PMID: 34680299 PMCID: PMC8534213 DOI: 10.3390/cancers13205150] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2021] [Revised: 10/08/2021] [Accepted: 10/09/2021] [Indexed: 11/16/2022] Open
Abstract
Tumor markers that can be detected at an early stage are needed. Here, we evaluated the epiplakin expression levels in sera from patients with bladder cancer (BC). Using a micro-dot blot array, we evaluated epiplakin expression levels in 60 patients with BC, 20 patients with stone disease, and 28 healthy volunteers. The area under the curve (AUC) and best cut-off point were calculated using receiver-operating characteristic (ROC) analysis. Serum epiplakin levels were significantly higher in patients with BC than in those with stone disease (p = 0.0013) and in healthy volunteers (p < 0.0001). The AUC-ROC level for BC was 0.78 (95% confidence interval (CI) = 0.69-0.87). Using a cut-off point of 873, epiplakin expression levels exhibited 68.3% sensitivity and 79.2% specificity for BC. However, the serum epiplakin levels did not significantly differ by sex, age, pathological stage and grade, or urine cytology. We performed immunohistochemical staining using the same antibody on another cohort of 127 patients who underwent radical cystectomy. Univariate and multivariate analysis results showed no significant differences between epiplakin expression, clinicopathological findings, and patient prognoses. Our results showed that serum epiplakin might be a potential serodiagnostic biomarker in patients with BC.
Collapse
|
|
5
|
Koguchi D, Matsumoto K, Shimizu Y, Kobayashi M, Hirano S, Ikeda M, Sato Y, Iwamura M. Prognostic Impact of AHNAK2 Expression in Patients Treated with Radical Cystectomy. Cancers (Basel) 2021; 13:cancers13081748. [PMID: 33918555 PMCID: PMC8069489 DOI: 10.3390/cancers13081748] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2021] [Revised: 04/01/2021] [Accepted: 04/06/2021] [Indexed: 12/20/2022] Open
Abstract
Data regarding expression levels of AHNAK2 in bladder cancer (BCa) have been very scarce. We retrospectively reviewed clinical data including clinicopathological features in 120 patients who underwent radical cystectomy (RC) for BCa. The expression levels of AHNAK2 in the specimens obtained by RC were classified as low expression (LE) or high expression (HE) by immunohistochemical staining. Statistical analyses were performed to compare associations between the two AHNAK2 expression patterns and the prognoses in terms of recurrence-free survival (RFS) and cancer-specific survival (CSS). A Kaplan-Meier analysis showed that patients with HE had a significantly worse RFS and CSS than those with LE (hazard ratio [HR]: 1.78, 95% confidence interval [CI]: 1.02-2.98, p = 0.027 and HR: 1.91, 95% CI: 1.08-3.38, p = 0.023, respectively). In a multivariate analysis, independent risk factors for worse RFS and CSS were shown as HE (HR: 1.96, 95% CI: 1.08-3.53, p = 0.026 and HR: 2.22, 95% CI: 1.14-4.31, p = 0.019, respectively) and lymph node metastasis (HR: 2.04, 95% CI: 1.09-3.84, p = 0.026 and HR: 1.19, 95% CI: 1.25-4.97, p = 0.009, respectively). The present study showed that AHNAK2 acts as a novel prognostic biomarker in patients with RC for BCa.
Collapse
|
|
6
|
Lee H, Kim K, Woo J, Park J, Kim H, Lee KE, Kim H, Kim Y, Moon KC, Kim JY, Park IA, Shim BB, Moon JH, Han D, Ryu HS. Quantitative Proteomic Analysis Identifies AHNAK (Neuroblast Differentiation-associated Protein AHNAK) as a Novel Candidate Biomarker for Bladder Urothelial Carcinoma Diagnosis by Liquid-based Cytology. Mol Cell Proteomics 2018; 17:1788-1802. [PMID: 29950347 DOI: 10.1074/mcp.ra118.000562] [Citation(s) in RCA: 59] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2018] [Revised: 06/25/2018] [Indexed: 01/04/2023] Open
Abstract
Cytological examination of urine is the most widely used noninvasive pathologic screen for bladder urothelial carcinoma (BLCA); however, inadequate diagnostic accuracy remains a major challenge. We performed mass spectrometry-based proteomic analysis of urine samples of ten patients with BLCA and ten paired patients with benign urothelial lesion (BUL) to identify ancillary proteomic markers for use in liquid-based cytology (LBC). A total of 4,839 proteins were identified and 112 proteins were confirmed as expressed at significantly different levels between the two groups. We also performed an independent proteomic profiling of tumor tissue samples where we identified 7,916 proteins of which 758 were differentially expressed. Cross-platform comparisons of these data with comparative mRNA expression profiles from The Cancer Genome Atlas identified four putative candidate proteins, AHNAK, EPPK1, MYH14 and OLFM4. To determine their immunocytochemical expression levels in LBC, we examined protein expression data from The Human Protein Atlas and in-house FFPE samples. We further investigated the expression of the four candidate proteins in urine cytology samples from two independent validation cohorts. These analyses revealed AHNAK as a unique intracellular protein differing in immunohistochemical expression and subcellular localization between tumor and non-tumor cells. In conclusion, this study identified a new biomarker, AHNAK, applicable to discrimination between BLCA and BUL by LBC. To our knowledge, the present study provides the first identification of a clinical biomarker for LBC based on in-depth proteomics.
Collapse
Affiliation(s)
- Hyebin Lee
- From the ‡Department of Radiation Oncology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea
| | - Kwangsoo Kim
- §Division of Clinical Bioinformatics, Biomedical Research Institute, Seoul National University Hospital, Seoul, South Korea
| | - Jongmin Woo
- ¶Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, South Korea
| | - Joonho Park
- ¶Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, South Korea
| | - Hyeyoon Kim
- ‖Proteomics Core Facility, Biomedical Research Institute, Seoul National University Hospital, Seoul, South Korea.,**Department of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea
| | - Kyung Eun Lee
- ‡‡Department of Statistics, Korea University, Seoul, South Korea
| | - Hyeyeon Kim
- ‖Proteomics Core Facility, Biomedical Research Institute, Seoul National University Hospital, Seoul, South Korea
| | - Youngsoo Kim
- ¶Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, South Korea
| | - Kyung Chul Moon
- **Department of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea
| | - Ji Young Kim
- **Department of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea
| | - In Ae Park
- **Department of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea
| | - Bo Bae Shim
- **Department of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea
| | - Ji Hye Moon
- **Department of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea
| | - Dohyun Han
- §Division of Clinical Bioinformatics, Biomedical Research Institute, Seoul National University Hospital, Seoul, South Korea; .,‖Proteomics Core Facility, Biomedical Research Institute, Seoul National University Hospital, Seoul, South Korea
| | - Han Suk Ryu
- **Department of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea;
| |
Collapse
|
|
7
|
Li X, Zhang G, Wang Y, Elgehama A, Sun Y, Li L, Gu Y, Guo W, Xu Q. Loss of periplakin expression is associated with the tumorigenesis of colorectal carcinoma. Biomed Pharmacother 2017; 87:366-374. [PMID: 28068625 DOI: 10.1016/j.biopha.2016.12.103] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2016] [Revised: 12/19/2016] [Accepted: 12/21/2016] [Indexed: 10/20/2022] Open
Abstract
Periplakin (PPL), a member of the plakin protein family, has been reported to be down-expressed in urothelial carcinoma. The role of PPL in human colorectal cancer, however, remains largely unknown. Also little is known about the contribution of PPL to the malignant property of colorectal cancer and the intracellular function of PPL. In this study, we demonstrated that PPL was apparently down-expressed in colon carcinomas compared with normal and para-carcinoma tissues, which was correlated with the tumor size. Enforced expression of PPL in HT29 cells inhibited its proliferation evidenced by decreased expression of phosphorylated ERK and PCNA. Furthermore, PPL overexpression could reduce metastasis and epithelial-mesenchymal transition (EMT) of HT29 cells, with decreased expression of N-cadherin, Snail, Slug and α-SMA while increased expression of E-cadherin. On the contrary, the PPL knockdown could promote the cell proliferation, migratory, invasive and EMT ability of HT29 cells. Moreover, enforced expression of PPL induced G1/G0 cell cycle arrest, with decreased cyclin D1, p-Rb and increased expression of p27kib, which could be reversed by PPL knockdown. In addition, PPL overexpression inhibited the growth of colon cancer allograft in vivo. Taken together, acted as a tumor suppressor in colon cancer progression, PPL could be a new biomarker or potential therapeutic target in colon cancer.
Collapse
Affiliation(s)
- Xiang Li
- State Key Laboratory of Pharmaceutical Biotechnology, School of Life Science, Nanjing University, 163 Xianlin Avenue, Nanjing 210023, China
| | - Guohui Zhang
- State Key Laboratory of Pharmaceutical Biotechnology, School of Life Science, Nanjing University, 163 Xianlin Avenue, Nanjing 210023, China
| | - Yan Wang
- State Key Laboratory of Pharmaceutical Biotechnology, School of Life Science, Nanjing University, 163 Xianlin Avenue, Nanjing 210023, China
| | - Ahmed Elgehama
- State Key Laboratory of Pharmaceutical Biotechnology, School of Life Science, Nanjing University, 163 Xianlin Avenue, Nanjing 210023, China
| | - Yang Sun
- State Key Laboratory of Pharmaceutical Biotechnology, School of Life Science, Nanjing University, 163 Xianlin Avenue, Nanjing 210023, China
| | - Lele Li
- Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China
| | - Yanhong Gu
- Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
| | - Wenjie Guo
- State Key Laboratory of Pharmaceutical Biotechnology, School of Life Science, Nanjing University, 163 Xianlin Avenue, Nanjing 210023, China.
| | - Qiang Xu
- State Key Laboratory of Pharmaceutical Biotechnology, School of Life Science, Nanjing University, 163 Xianlin Avenue, Nanjing 210023, China.
| |
Collapse
|
|
8
|
[EXPRESSION OF PLAKIN FAMILY IN UROTHELIAL CARCINOMA OF THE UPPER URINARY TRACT]. Nihon Hinyokika Gakkai Zasshi 2017; 108:87-95. [PMID: 29669982 DOI: 10.5980/jpnjurol.108.87] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
(Objective) To determine whether the plakin family proteins periplakin, desmoplakin, plectin, and envoplakin could be markers of urothelial carcinoma of the upper urinary tract. (Materials and methods) Fifty-seven surgical specimens were obtained from patients with urothelial carcinoma of the upper urinary tract, who were admitted to the Jikei University Hospital between April 2000 and December 2005. The expression of plakin family proteins in cancerous and normal tissues was investigated using immunohistochemistry, and its association with clinicopathological parameters was analyzed. (Results) The expression of periplakin, envoplakin, and desmoplakin was significantly lower in cancerous tissue than in normal urothelium (P < 0.0001, P < 0.0001, and P < 0.0001, respectively). Strong desmoplakin expression in cancerous tissue was significantly associated with poor cancer-specific survival and overall survival (P = 0.023 and P = 0.034, respectively, compared with cancerous tissue with slight or less desmoplakin expression). Furthermore, strong plectin expression was significantly associated with poor metastasis-free survival (P = 0.034, compared with cancerous tissue with slight or less plectin expression). (Conclusion) Plakin family, particularly desmoplakin was suggested to be a prognostic marker of urothelial carcinoma of the upper urinary tract.
Collapse
|
|
9
|
TAOKA Y, MATSUMOTO K, OHASHI K, MINAMIDA S, HAGIWARA M, NAGI S, SAITO T, KODERA Y, IWAMURA M. Protein expression profile related to cisplatin resistance in bladder cancer cell lines detected by two-dimensional gel electrophoresis . Biomed Res 2015; 36:253-61. [DOI: 10.2220/biomedres.36.253] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Affiliation(s)
- Yoshinori TAOKA
- Department of Urology, Kitasato University School of Medicine
| | | | - Kazuya OHASHI
- Department of Physics, Kitasato University School of Science
| | - Satoru MINAMIDA
- Department of Urology, Kitasato University School of Medicine
| | | | - Shoji NAGI
- Department of Urology, Kitasato University School of Medicine
| | - Tatsuya SAITO
- Department of Physics, Kitasato University School of Science
| | - Yoshio KODERA
- Department of Physics, Kitasato University School of Science
| | | |
Collapse
|
|
10
|
MATSUMOTO K, IKEDA M, SATO Y, KURUMA H, KAMATA Y, NISHIMORI T, TOMONAGA T, NOMURA F, EGAWA S, IWAMURA M. Loss of periplakin expression is associated with pathological stage and cancerspecific survival in patients with urothelial carcinoma of the urinary bladder. Biomed Res 2014; 35:201-6. [DOI: 10.2220/biomedres.35.201] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
|
11
|
Abstract
Two-dimensional electrophoresis (2-DE) is a high-resolution technique for analysis and comparison of complex protein mixtures. With the advent of recent technical developments, its application has become significant in a wide range of fields. This chapter describes a proteomic approach for the analysis of metastasis-associated proteins using pre-fractionation of glycosylated proteins via lectin (HPA) affinity chromatography prior to separation by 2-DE. Guidelines for the preparation and storage of buffers, experimental conditions and protocols of affinity chromatography, isoelectric focussing, and SDS-PAGE conditions are provided. Critical parameters associated with the different steps of 2-DE are discussed.
Collapse
Affiliation(s)
- Miriam Dwek
- Department of Molecular and Applied Biosciences, School of Life Sciences, University of Westminster, London, UK.
| | | |
Collapse
|